The IFI27L2 Knockout HeLa Polyclonal Cells product provides a heterogeneous population of HeLa cells engineered through CRISPR/Cas9-mediated gene disruption of the IFI27L2 locus, generating a loss-of-function model for the interferon-inducible protein IFI27L2. As a polyclonal knockout cell pool, this product preserves the genetic diversity inherent to genome editing, enabling robust functional analysis without the selective bottlenecks of single-cell cloning. The absence of IFI27L2 expression allows researchers to dissect the gene’s role in apoptotic and antiviral signaling pathways within a well-characterized cervical cancer background.
HeLa cells are a widely employed human epithelial cell line derived from a cervical adenocarcinoma positive for human papillomavirus type 18 (HPV-18). This immortalized line exhibits high proliferative capacity and serves as a versatile platform for functional genomics, cancer biology, and virology research. The epithelial morphology and stable growth characteristics make HeLa cells particularly suitable for investigations requiring reproducible and scalable experimental conditions, including drug screening, signal transduction studies, and host-pathogen interaction assays.
IFI27L2 is an interferon-stimulated gene (ISG) encoding a mitochondrial protein that promotes apoptosis upon viral infection. The type I interferon pathway, via IFNAR1/IFNAR2 receptor engagement, activates JAK1 and TYK2 to phosphorylate STAT1 and STAT2. These bind IRF9 to form the ISGF3 transcription complex, inducing IFI27L2 and other ISGs. The IFI27L2 protein interacts with Bcl-2 family members and mitochondrial proteins to facilitate caspase activation and cell death, linking innate immune signaling to apoptotic execution.
In the HPV-18 positive HeLa background, apoptotic pathways are frequently dysregulated due to viral oncoprotein expression, making the IFI27L2 knockout a valuable tool for disentangling interferon-induced apoptosis from other cell death modalities. Abrogation of IFI27L2 expression in HeLa cells can blunt interferon-mediated cell killing, providing a controlled system to study how cancer cells evade antiviral defense mechanisms and how interferon responses can be therapeutically targeted. This model is particularly relevant for investigating the cross-talk between persistent viral oncogene expression and innate immune signaling, offering insights that may extend to cervical carcinogenesis and other HPV-associated malignancies.
Researchers can utilize this polyclonal knockout cell population for western blot detection of cleaved caspase-3, RT-qPCR quantification of ISG transcripts, and Annexin V/PI apoptosis assays. Additional applications include interferon-responsive reporter gene assays, viral replication kinetics, global transcriptomic profiling via RNA-seq, and co-immunoprecipitation for protein interaction analysis. This model aids in dissecting interferon-induced apoptosis and supports drug target validation in infectious disease and oncology. For technical inquiries, contact Ascent Research.
